CYP19A1 and breast cancer: Additionally, 85.7% of BC patients had a luminal phenotype that required adjuvant endocrine therapy (72.3% aromatase inhibitors-based and 27.7% tamoxifen-based) and 62.2% of patients also received adjuvant chemotherapy.